| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 112 | 2024 | 3697 | 9.830 |
Why?
|
| DNA Mismatch Repair | 28 | 2024 | 279 | 5.800 |
Why?
|
| Intestinal Neoplasms | 14 | 2021 | 201 | 5.630 |
Why?
|
| Appendiceal Neoplasms | 23 | 2024 | 251 | 5.230 |
Why?
|
| Microsatellite Instability | 42 | 2024 | 410 | 5.230 |
Why?
|
| Adenocarcinoma | 61 | 2024 | 7971 | 4.690 |
Why?
|
| Intestine, Small | 15 | 2021 | 526 | 3.990 |
Why?
|
| Ampulla of Vater | 15 | 2020 | 158 | 3.740 |
Why?
|
| Common Bile Duct Neoplasms | 14 | 2017 | 150 | 3.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 65 | 2024 | 16606 | 3.130 |
Why?
|
| Colonic Neoplasms | 20 | 2024 | 1443 | 2.630 |
Why?
|
| Adenocarcinoma, Mucinous | 12 | 2023 | 443 | 2.210 |
Why?
|
| Duodenal Neoplasms | 11 | 2021 | 139 | 2.150 |
Why?
|
| Organoplatinum Compounds | 20 | 2020 | 704 | 1.760 |
Why?
|
| Peritoneal Neoplasms | 13 | 2023 | 852 | 1.750 |
Why?
|
| Research Report | 3 | 2018 | 144 | 1.720 |
Why?
|
| Antibodies, Monoclonal, Humanized | 18 | 2024 | 3391 | 1.690 |
Why?
|
| Pancreatic Neoplasms | 31 | 2024 | 5246 | 1.670 |
Why?
|
| Antineoplastic Agents, Immunological | 10 | 2023 | 1335 | 1.590 |
Why?
|
| Medical Oncology | 11 | 2024 | 1462 | 1.530 |
Why?
|
| Biomarkers, Tumor | 42 | 2024 | 10743 | 1.450 |
Why?
|
| Carcinoma, Pancreatic Ductal | 16 | 2024 | 1824 | 1.430 |
Why?
|
| Aged | 135 | 2024 | 73421 | 1.410 |
Why?
|
| Middle Aged | 153 | 2024 | 90349 | 1.390 |
Why?
|
| Antibodies, Monoclonal | 17 | 2024 | 4495 | 1.370 |
Why?
|
| Biopsy | 6 | 2023 | 3544 | 1.370 |
Why?
|
| Immunotherapy | 14 | 2024 | 3539 | 1.350 |
Why?
|
| Humans | 258 | 2024 | 271636 | 1.340 |
Why?
|
| Programmed Cell Death 1 Receptor | 9 | 2023 | 1089 | 1.330 |
Why?
|
| Antineoplastic Agents | 33 | 2023 | 14653 | 1.320 |
Why?
|
| Bevacizumab | 12 | 2024 | 957 | 1.270 |
Why?
|
| Clinical Trials as Topic | 10 | 2020 | 3852 | 1.270 |
Why?
|
| Endpoint Determination | 3 | 2024 | 183 | 1.260 |
Why?
|
| Male | 164 | 2024 | 128836 | 1.240 |
Why?
|
| Adult | 121 | 2024 | 81791 | 1.240 |
Why?
|
| Liver Neoplasms | 24 | 2024 | 4805 | 1.210 |
Why?
|
| Mutation | 43 | 2024 | 15913 | 1.160 |
Why?
|
| Neoplasms | 27 | 2024 | 15903 | 1.150 |
Why?
|
| Aged, 80 and over | 74 | 2024 | 31032 | 1.140 |
Why?
|
| Neoplasms, Unknown Primary | 7 | 2023 | 199 | 1.120 |
Why?
|
| Female | 160 | 2024 | 148992 | 1.110 |
Why?
|
| Pseudomyxoma Peritonei | 4 | 2015 | 41 | 1.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 17 | 2023 | 1408 | 0.990 |
Why?
|
| Camptothecin | 11 | 2020 | 538 | 0.980 |
Why?
|
| Ipilimumab | 6 | 2022 | 759 | 0.980 |
Why?
|
| Molecular Targeted Therapy | 10 | 2019 | 2398 | 0.960 |
Why?
|
| Prognosis | 60 | 2023 | 22525 | 0.960 |
Why?
|
| Neoadjuvant Therapy | 19 | 2023 | 5209 | 0.960 |
Why?
|
| Neoplasm Metastasis | 29 | 2024 | 5328 | 0.950 |
Why?
|
| Retrospective Studies | 73 | 2024 | 39731 | 0.910 |
Why?
|
| Albumins | 4 | 2022 | 267 | 0.900 |
Why?
|
| ErbB Receptors | 11 | 2019 | 2383 | 0.890 |
Why?
|
| Metastasectomy | 5 | 2021 | 209 | 0.880 |
Why?
|
| Disease-Free Survival | 31 | 2021 | 10259 | 0.840 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2020 | 5420 | 0.830 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 2672 | 0.810 |
Why?
|
| Fluorouracil | 19 | 2023 | 1988 | 0.790 |
Why?
|
| Survival Rate | 38 | 2023 | 12530 | 0.790 |
Why?
|
| Jejunal Neoplasms | 4 | 2021 | 33 | 0.770 |
Why?
|
| Ileal Neoplasms | 4 | 2021 | 49 | 0.760 |
Why?
|
| Paclitaxel | 7 | 2024 | 2099 | 0.760 |
Why?
|
| Cytoreduction Surgical Procedures | 7 | 2023 | 508 | 0.760 |
Why?
|
| Neoplasm Staging | 29 | 2023 | 13989 | 0.730 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 204 | 0.700 |
Why?
|
| Deoxycytidine | 10 | 2022 | 1378 | 0.690 |
Why?
|
| CpG Islands | 7 | 2020 | 662 | 0.690 |
Why?
|
| Proto-Oncogene Proteins B-raf | 13 | 2023 | 1331 | 0.680 |
Why?
|
| Treatment Outcome | 49 | 2022 | 33846 | 0.660 |
Why?
|
| Cetuximab | 10 | 2017 | 474 | 0.660 |
Why?
|
| DNA Methylation | 10 | 2019 | 2759 | 0.660 |
Why?
|
| Health | 1 | 2019 | 51 | 0.650 |
Why?
|
| Organ Dysfunction Scores | 1 | 2018 | 70 | 0.640 |
Why?
|
| Kaplan-Meier Estimate | 25 | 2021 | 6266 | 0.640 |
Why?
|
| Trifluridine | 2 | 2008 | 28 | 0.630 |
Why?
|
| Uracil | 2 | 2008 | 67 | 0.630 |
Why?
|
| Vimentin | 2 | 2016 | 260 | 0.620 |
Why?
|
| Biomedical Research | 2 | 2018 | 801 | 0.620 |
Why?
|
| Follow-Up Studies | 31 | 2022 | 15254 | 0.610 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2019 | 180 | 0.600 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2020 | 624 | 0.590 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 323 | 0.580 |
Why?
|
| Gene Expression Profiling | 8 | 2023 | 5180 | 0.570 |
Why?
|
| Watchful Waiting | 3 | 2022 | 292 | 0.570 |
Why?
|
| Rectal Neoplasms | 6 | 2022 | 1240 | 0.570 |
Why?
|
| Pyrazines | 1 | 2020 | 513 | 0.560 |
Why?
|
| Thrombocytopenia | 2 | 2020 | 871 | 0.550 |
Why?
|
| Leucovorin | 11 | 2023 | 344 | 0.550 |
Why?
|
| Registries | 4 | 2019 | 2246 | 0.540 |
Why?
|
| Neoplasm Grading | 10 | 2020 | 1827 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2023 | 10354 | 0.520 |
Why?
|
| Intestinal Obstruction | 2 | 2015 | 224 | 0.520 |
Why?
|
| Publication Bias | 1 | 2015 | 37 | 0.510 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2015 | 138 | 0.510 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 1059 | 0.510 |
Why?
|
| Circulating Tumor DNA | 3 | 2023 | 271 | 0.500 |
Why?
|
| Lung Neoplasms | 12 | 2024 | 12008 | 0.500 |
Why?
|
| Research Design | 3 | 2020 | 1580 | 0.490 |
Why?
|
| Mucin-1 | 1 | 2015 | 164 | 0.480 |
Why?
|
| ras Proteins | 9 | 2019 | 802 | 0.480 |
Why?
|
| Benzamides | 1 | 2020 | 1882 | 0.470 |
Why?
|
| Young Adult | 30 | 2021 | 22094 | 0.460 |
Why?
|
| Calcinosis | 1 | 2017 | 431 | 0.460 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 247 | 0.460 |
Why?
|
| B7-H1 Antigen | 4 | 2022 | 1072 | 0.460 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 4 | 2024 | 118 | 0.460 |
Why?
|
| Intensive Care Units | 1 | 2018 | 742 | 0.450 |
Why?
|
| Critical Illness | 1 | 2018 | 741 | 0.430 |
Why?
|
| Receptor, ErbB-2 | 3 | 2018 | 2649 | 0.430 |
Why?
|
| Pancreatectomy | 5 | 2022 | 696 | 0.430 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 522 | 0.420 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1315 | 0.420 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 2999 | 0.410 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2429 | 0.410 |
Why?
|
| Hepatectomy | 12 | 2022 | 1013 | 0.410 |
Why?
|
| Capecitabine | 5 | 2022 | 390 | 0.400 |
Why?
|
| Combined Modality Therapy | 14 | 2023 | 9042 | 0.400 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 1134 | 0.400 |
Why?
|
| Pancreaticoduodenectomy | 7 | 2017 | 706 | 0.390 |
Why?
|
| Cohort Studies | 16 | 2023 | 9467 | 0.390 |
Why?
|
| Carcinoma | 3 | 2019 | 2623 | 0.380 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 3538 | 0.380 |
Why?
|
| Proportional Hazards Models | 11 | 2018 | 5113 | 0.380 |
Why?
|
| Preoperative Care | 6 | 2021 | 1550 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 9093 | 0.370 |
Why?
|
| Hyperthermia, Induced | 4 | 2023 | 510 | 0.370 |
Why?
|
| Hypersplenism | 2 | 2020 | 23 | 0.360 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2024 | 484 | 0.360 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 92 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2024 | 7788 | 0.350 |
Why?
|
| Pulmonary Alveoli | 1 | 2011 | 223 | 0.350 |
Why?
|
| Microsatellite Repeats | 3 | 2022 | 629 | 0.340 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2023 | 233 | 0.340 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 3363 | 0.340 |
Why?
|
| Survival Analysis | 19 | 2023 | 9323 | 0.330 |
Why?
|
| Patient Selection | 7 | 2020 | 2043 | 0.330 |
Why?
|
| Splenomegaly | 1 | 2010 | 173 | 0.330 |
Why?
|
| Informed Consent | 1 | 2012 | 413 | 0.330 |
Why?
|
| Hospitalization | 1 | 2018 | 2202 | 0.330 |
Why?
|
| Prospective Studies | 15 | 2024 | 13385 | 0.330 |
Why?
|
| Data Accuracy | 2 | 2019 | 47 | 0.320 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 135 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2020 | 1346 | 0.310 |
Why?
|
| Lymphoma, Follicular | 2 | 2017 | 636 | 0.310 |
Why?
|
| Liver | 4 | 2024 | 3123 | 0.310 |
Why?
|
| Feasibility Studies | 7 | 2023 | 2348 | 0.300 |
Why?
|
| Antigens, Neoplasm | 5 | 2023 | 1589 | 0.300 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 347 | 0.300 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2019 | 640 | 0.290 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2019 | 232 | 0.290 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2024 | 1013 | 0.280 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 565 | 0.280 |
Why?
|
| Ascites | 2 | 2022 | 216 | 0.280 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2018 | 398 | 0.280 |
Why?
|
| Receptors, Somatomedin | 2 | 2018 | 73 | 0.280 |
Why?
|
| Oncogenes | 1 | 2009 | 701 | 0.270 |
Why?
|
| DNA Mutational Analysis | 6 | 2019 | 2365 | 0.270 |
Why?
|
| Administration, Oral | 4 | 2020 | 1618 | 0.270 |
Why?
|
| Lymphatic Metastasis | 10 | 2023 | 4967 | 0.260 |
Why?
|
| Carcinoembryonic Antigen | 3 | 2024 | 237 | 0.260 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 736 | 0.260 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2023 | 481 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2020 | 3976 | 0.260 |
Why?
|
| Quality of Life | 2 | 2022 | 4745 | 0.260 |
Why?
|
| Lymph Nodes | 4 | 2021 | 3069 | 0.250 |
Why?
|
| Pyrimidines | 2 | 2020 | 3663 | 0.250 |
Why?
|
| Disease Management | 3 | 2019 | 1111 | 0.250 |
Why?
|
| Communication | 1 | 2011 | 854 | 0.250 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 408 | 0.250 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1729 | 0.250 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 14 | 0.250 |
Why?
|
| Stomach Neoplasms | 3 | 2022 | 2317 | 0.240 |
Why?
|
| Pilot Projects | 5 | 2023 | 2853 | 0.240 |
Why?
|
| Spleen | 3 | 2020 | 732 | 0.240 |
Why?
|
| Embolization, Therapeutic | 2 | 2020 | 605 | 0.240 |
Why?
|
| DNA Polymerase III | 1 | 2024 | 31 | 0.240 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 864 | 0.240 |
Why?
|
| DNA Polymerase II | 1 | 2024 | 59 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 6 | 2020 | 3262 | 0.230 |
Why?
|
| Chemoradiotherapy | 6 | 2021 | 2029 | 0.230 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2004 | 64 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2015 | 2624 | 0.230 |
Why?
|
| Multivariate Analysis | 9 | 2021 | 4352 | 0.220 |
Why?
|
| Sulfonamides | 3 | 2020 | 1918 | 0.220 |
Why?
|
| Signal Transduction | 5 | 2020 | 12219 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 5744 | 0.220 |
Why?
|
| Liquid Biopsy | 2 | 2021 | 162 | 0.220 |
Why?
|
| Thioguanine | 1 | 2023 | 70 | 0.220 |
Why?
|
| CDX2 Transcription Factor | 2 | 2015 | 35 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 340 | 0.210 |
Why?
|
| Tumor Burden | 4 | 2021 | 2035 | 0.210 |
Why?
|
| CTLA-4 Antigen | 3 | 2022 | 681 | 0.200 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 58 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2021 | 1588 | 0.200 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 4998 | 0.200 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2020 | 103 | 0.200 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 1972 | 0.200 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1101 | 0.190 |
Why?
|
| Genes, ras | 3 | 2021 | 681 | 0.190 |
Why?
|
| Retreatment | 2 | 2015 | 447 | 0.190 |
Why?
|
| Organ Size | 2 | 2024 | 727 | 0.190 |
Why?
|
| Time Factors | 9 | 2024 | 13116 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2024 | 338 | 0.190 |
Why?
|
| Membrane Proteins | 3 | 2021 | 2973 | 0.190 |
Why?
|
| Policy | 1 | 2021 | 53 | 0.190 |
Why?
|
| Support Vector Machine | 1 | 2020 | 42 | 0.180 |
Why?
|
| Splenic Infarction | 1 | 2020 | 13 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5566 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2015 | 2335 | 0.180 |
Why?
|
| Rare Diseases | 2 | 2023 | 360 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 4 | 2018 | 1323 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2022 | 317 | 0.180 |
Why?
|
| Perioperative Period | 1 | 2021 | 150 | 0.180 |
Why?
|
| CA-19-9 Antigen | 4 | 2024 | 155 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3924 | 0.180 |
Why?
|
| Disease Progression | 9 | 2021 | 6905 | 0.180 |
Why?
|
| Drug Combinations | 3 | 2021 | 634 | 0.180 |
Why?
|
| Endoscopy | 1 | 2023 | 497 | 0.180 |
Why?
|
| Rivaroxaban | 1 | 2020 | 58 | 0.180 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 166 | 0.170 |
Why?
|
| Mutation, Missense | 2 | 2017 | 1198 | 0.170 |
Why?
|
| Salvage Therapy | 3 | 2019 | 2118 | 0.170 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 59 | 0.170 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 4993 | 0.170 |
Why?
|
| Pyridones | 1 | 2022 | 361 | 0.170 |
Why?
|
| Boron Compounds | 1 | 2020 | 69 | 0.170 |
Why?
|
| Antiemetics | 1 | 2021 | 122 | 0.170 |
Why?
|
| Inflammation | 3 | 2019 | 2532 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 63 | 0.170 |
Why?
|
| Aspirin | 1 | 2022 | 392 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 533 | 0.170 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 1340 | 0.170 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2019 | 7 | 0.170 |
Why?
|
| Safety | 1 | 2021 | 466 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 1657 | 0.160 |
Why?
|
| Platelet Count | 3 | 2020 | 491 | 0.160 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2020 | 181 | 0.160 |
Why?
|
| Treatment Failure | 2 | 2017 | 1432 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2023 | 417 | 0.160 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 341 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 157 | 0.160 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 910 | 0.160 |
Why?
|
| ROC Curve | 2 | 2020 | 1248 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 251 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2015 | 1719 | 0.160 |
Why?
|
| Genetic Testing | 2 | 2019 | 1694 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 277 | 0.160 |
Why?
|
| Microfluidics | 1 | 2018 | 32 | 0.160 |
Why?
|
| Publications | 1 | 2018 | 54 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2023 | 681 | 0.160 |
Why?
|
| Thymine | 2 | 2008 | 45 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.160 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 148 | 0.150 |
Why?
|
| Receptor, ErbB-3 | 1 | 2018 | 126 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1439 | 0.150 |
Why?
|
| Appendectomy | 2 | 2016 | 127 | 0.150 |
Why?
|
| Pyrrolidines | 2 | 2008 | 114 | 0.150 |
Why?
|
| Cytokines | 3 | 2017 | 2837 | 0.150 |
Why?
|
| Genetic Techniques | 1 | 2018 | 155 | 0.150 |
Why?
|
| SEER Program | 2 | 2013 | 1046 | 0.150 |
Why?
|
| Phenotype | 6 | 2020 | 6510 | 0.150 |
Why?
|
| Glycine | 1 | 2020 | 319 | 0.150 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 369 | 0.150 |
Why?
|
| Adolescent | 11 | 2021 | 32609 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 507 | 0.150 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2018 | 273 | 0.150 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2017 | 81 | 0.150 |
Why?
|
| Palliative Care | 4 | 2020 | 2156 | 0.150 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 128 | 0.140 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 144 | 0.140 |
Why?
|
| Mice, SCID | 2 | 2019 | 1851 | 0.140 |
Why?
|
| Tumor Escape | 1 | 2019 | 248 | 0.140 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2017 | 76 | 0.140 |
Why?
|
| Outpatients | 1 | 2020 | 469 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 335 | 0.140 |
Why?
|
| src-Family Kinases | 2 | 2017 | 487 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 672 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 3670 | 0.140 |
Why?
|
| Mutation Rate | 1 | 2017 | 220 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 544 | 0.140 |
Why?
|
| Colectomy | 3 | 2016 | 290 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2019 | 4963 | 0.140 |
Why?
|
| Epiregulin | 1 | 2016 | 14 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 7463 | 0.140 |
Why?
|
| Amphiregulin | 1 | 2016 | 33 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 343 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2022 | 2287 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2023 | 2349 | 0.140 |
Why?
|
| Peritoneum | 1 | 2017 | 150 | 0.140 |
Why?
|
| Etoposide | 1 | 2018 | 905 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 5067 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2019 | 531 | 0.140 |
Why?
|
| Biological Products | 1 | 2020 | 316 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 1014 | 0.140 |
Why?
|
| Dasatinib | 2 | 2017 | 881 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 731 | 0.130 |
Why?
|
| Animals | 10 | 2023 | 62757 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2010 | 3240 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 662 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2021 | 560 | 0.130 |
Why?
|
| Colitis | 1 | 2019 | 344 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 2128 | 0.130 |
Why?
|
| Incidence | 5 | 2023 | 5856 | 0.130 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 102 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1020 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2016 | 85 | 0.130 |
Why?
|
| Benzodioxoles | 1 | 2015 | 29 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 92 | 0.130 |
Why?
|
| Carboplatin | 1 | 2018 | 879 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1387 | 0.130 |
Why?
|
| Transcriptome | 3 | 2020 | 1940 | 0.130 |
Why?
|
| Cachexia | 1 | 2017 | 168 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 376 | 0.120 |
Why?
|
| Appendix | 1 | 2015 | 45 | 0.120 |
Why?
|
| Re-Irradiation | 1 | 2017 | 166 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2015 | 125 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 498 | 0.120 |
Why?
|
| Placebos | 4 | 2020 | 446 | 0.120 |
Why?
|
| Aluminum Silicates | 1 | 2014 | 16 | 0.120 |
Why?
|
| Diaphragm | 1 | 2016 | 187 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 882 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 789 | 0.120 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 14868 | 0.120 |
Why?
|
| Double-Blind Method | 5 | 2021 | 2619 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2021 | 5504 | 0.120 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 99 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 895 | 0.120 |
Why?
|
| Goblet Cells | 1 | 2015 | 118 | 0.120 |
Why?
|
| Thioctic Acid | 1 | 2013 | 14 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2019 | 1066 | 0.120 |
Why?
|
| Genes, erbB-1 | 2 | 2015 | 104 | 0.120 |
Why?
|
| United States | 6 | 2024 | 16036 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2020 | 2457 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2015 | 758 | 0.120 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2014 | 116 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2018 | 684 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 744 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 4070 | 0.110 |
Why?
|
| Adenoma | 1 | 2019 | 745 | 0.110 |
Why?
|
| Mice | 5 | 2023 | 36006 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 7817 | 0.110 |
Why?
|
| Gene Amplification | 1 | 2016 | 770 | 0.110 |
Why?
|
| Taxoids | 2 | 2023 | 1010 | 0.110 |
Why?
|
| Methylphenidate | 1 | 2014 | 91 | 0.110 |
Why?
|
| Celecoxib | 1 | 2013 | 203 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2020 | 2495 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 428 | 0.110 |
Why?
|
| Quinazolines | 2 | 2015 | 953 | 0.110 |
Why?
|
| Survival | 1 | 2013 | 184 | 0.110 |
Why?
|
| Carcinoid Tumor | 1 | 2015 | 282 | 0.110 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4795 | 0.110 |
Why?
|
| Fatigue | 2 | 2023 | 1280 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 445 | 0.110 |
Why?
|
| Preoperative Period | 3 | 2020 | 349 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 1264 | 0.100 |
Why?
|
| Genomics | 2 | 2023 | 2830 | 0.100 |
Why?
|
| Cisplatin | 4 | 2015 | 2497 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 126 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 967 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 3171 | 0.100 |
Why?
|
| Pathologists | 2 | 2023 | 101 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2021 | 6230 | 0.100 |
Why?
|
| Protein Binding | 1 | 2018 | 3526 | 0.100 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 379 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1555 | 0.100 |
Why?
|
| Cyclin D1 | 1 | 2014 | 591 | 0.100 |
Why?
|
| Beneficence | 1 | 2011 | 83 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 498 | 0.100 |
Why?
|
| Risk Assessment | 5 | 2020 | 6876 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2020 | 1368 | 0.090 |
Why?
|
| Mitomycin | 1 | 2012 | 214 | 0.090 |
Why?
|
| Gastrostomy | 1 | 2012 | 194 | 0.090 |
Why?
|
| Indoles | 1 | 2016 | 1034 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 505 | 0.090 |
Why?
|
| Diarrhea | 1 | 2014 | 730 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2016 | 2334 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 372 | 0.090 |
Why?
|
| Neutrophils | 1 | 2015 | 876 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 1327 | 0.090 |
Why?
|
| Melanoma | 2 | 2019 | 5591 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2016 | 5688 | 0.090 |
Why?
|
| Proteomics | 1 | 2017 | 1436 | 0.090 |
Why?
|
| Fibroblast Growth Factors | 1 | 2011 | 263 | 0.090 |
Why?
|
| Azacitidine | 1 | 2016 | 1218 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2015 | 1280 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 2435 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2011 | 179 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2015 | 741 | 0.080 |
Why?
|
| Thrombosis | 1 | 2015 | 751 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 1004 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4391 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2019 | 1781 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 835 | 0.080 |
Why?
|
| DNA | 1 | 2017 | 3088 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 228 | 0.080 |
Why?
|
| Nomograms | 2 | 2021 | 313 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1950 | 0.080 |
Why?
|
| Keratins | 1 | 2009 | 352 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2008 | 129 | 0.080 |
Why?
|
| Hypertension, Portal | 1 | 2009 | 129 | 0.080 |
Why?
|
| Mucins | 2 | 2023 | 289 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2023 | 453 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 364 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 1838 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2007 | 3131 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 5601 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 255 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 562 | 0.070 |
Why?
|
| Recurrence | 3 | 2019 | 4884 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 671 | 0.070 |
Why?
|
| Cause of Death | 1 | 2009 | 786 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2019 | 2912 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 5111 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 686 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 879 | 0.060 |
Why?
|
| Age of Onset | 2 | 2019 | 852 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6208 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2018 | 1241 | 0.060 |
Why?
|
| Prednisone | 1 | 2007 | 1037 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2013 | 1543 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2017 | 4191 | 0.060 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 356 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 2270 | 0.060 |
Why?
|
| Consensus | 2 | 2020 | 1115 | 0.060 |
Why?
|
| Contraindications | 1 | 2004 | 155 | 0.060 |
Why?
|
| Drug Approval | 2 | 2020 | 176 | 0.060 |
Why?
|
| Platelet Transfusion | 1 | 2004 | 167 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 617 | 0.060 |
Why?
|
| Vincristine | 1 | 2007 | 1572 | 0.060 |
Why?
|
| Massage | 1 | 2022 | 14 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 228 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 759 | 0.050 |
Why?
|
| Rituximab | 1 | 2007 | 1588 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 214 | 0.050 |
Why?
|
| Vital Signs | 1 | 2022 | 24 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 1094 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 5102 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2015 | 531 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 63 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 2471 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2013 | 206 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 124 | 0.050 |
Why?
|
| Vault Ribonucleoprotein Particles | 1 | 2000 | 3 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 72 | 0.050 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 18 | 0.050 |
Why?
|
| Biometry | 1 | 2023 | 247 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 253 | 0.050 |
Why?
|
| Quinuclidines | 1 | 2021 | 47 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 45 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 2574 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2021 | 125 | 0.040 |
Why?
|
| Chromogranins | 1 | 2020 | 88 | 0.040 |
Why?
|
| Splenic Artery | 1 | 2020 | 54 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 582 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 66 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2024 | 890 | 0.040 |
Why?
|
| Taiwan | 1 | 2020 | 99 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 25 | 0.040 |
Why?
|
| Texas | 3 | 2020 | 6434 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 3231 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2314 | 0.040 |
Why?
|
| Precision Medicine | 2 | 2018 | 1206 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2000 | 221 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2018 | 3512 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 115 | 0.040 |
Why?
|
| Japan | 1 | 2020 | 237 | 0.040 |
Why?
|
| Benchmarking | 1 | 2021 | 284 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2020 | 230 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4888 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 229 | 0.040 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2019 | 58 | 0.040 |
Why?
|
| Vomiting | 1 | 2021 | 361 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2000 | 319 | 0.040 |
Why?
|
| Survivorship | 1 | 2019 | 117 | 0.040 |
Why?
|
| Lipoxygenase | 1 | 2018 | 26 | 0.040 |
Why?
|
| Thromboxane-A Synthase | 1 | 2018 | 26 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 27 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2019 | 129 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 102 | 0.040 |
Why?
|
| Receptors, Prostaglandin | 1 | 2018 | 33 | 0.040 |
Why?
|
| Nausea | 1 | 2021 | 540 | 0.040 |
Why?
|
| Standard of Care | 1 | 2020 | 275 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1051 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 68 | 0.040 |
Why?
|
| Prostaglandins | 1 | 2018 | 84 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 668 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 18016 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 277 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2018 | 86 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 7222 | 0.040 |
Why?
|
| Indazoles | 1 | 2020 | 310 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2018 | 232 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 337 | 0.040 |
Why?
|
| Workflow | 1 | 2018 | 291 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2022 | 1510 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 253 | 0.030 |
Why?
|
| Obesity | 2 | 2022 | 2952 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 5195 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 342 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 522 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2021 | 1146 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 175 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1136 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 5804 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 16226 | 0.030 |
Why?
|
| Radiography | 1 | 2020 | 1991 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 4003 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2020 | 744 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 1482 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 354 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 366 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 479 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2017 | 251 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 1206 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 1388 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 544 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 2254 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2018 | 560 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 671 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1100 | 0.030 |
Why?
|
| Exosomes | 1 | 2017 | 253 | 0.030 |
Why?
|
| Codon | 1 | 2014 | 262 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1728 | 0.030 |
Why?
|
| Colon | 1 | 2017 | 690 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 2452 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 562 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2013 | 49 | 0.030 |
Why?
|
| Pyridines | 1 | 2021 | 1311 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 738 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 190 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 589 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 1376 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 179 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 1212 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 690 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 522 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 630 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4502 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 196 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 1242 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 541 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 1438 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 916 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 236 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 592 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1603 | 0.020 |
Why?
|
| Cell Movement | 1 | 2019 | 2503 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 428 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 1057 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 4370 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 3472 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 1597 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 1056 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 540 | 0.020 |
Why?
|
| Colorectal Surgery | 1 | 2010 | 35 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2016 | 1188 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4890 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 726 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2010 | 209 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 104 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 5499 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1740 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3922 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 6781 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3077 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3460 | 0.020 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1988 | 73 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5509 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 994 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 916 | 0.020 |
Why?
|
| Otitis Media | 1 | 1988 | 80 | 0.020 |
Why?
|
| Child | 2 | 2020 | 30401 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1988 | 191 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 887 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1547 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1574 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 329 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2085 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1988 | 300 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3423 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7292 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 3645 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1599 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 5996 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7929 | 0.010 |
Why?
|
| Genes, MDR | 1 | 2000 | 43 | 0.010 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2000 | 86 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 3651 | 0.010 |
Why?
|
| Chinchilla | 1 | 1988 | 4 | 0.000 |
Why?
|
| Ear, Middle | 1 | 1988 | 52 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 746 | 0.000 |
Why?
|
| Antibodies, Bacterial | 1 | 1988 | 420 | 0.000 |
Why?
|
| Streptococcus pneumoniae | 1 | 1988 | 404 | 0.000 |
Why?
|
| Sepsis | 1 | 1988 | 688 | 0.000 |
Why?
|